期刊文献+

阿米福汀在肺癌放射治疗时对机体正常细胞和肺癌细胞的影响 被引量:3

The radioprotective effects of amifostine on normal tissue cells and Lewis lung cancer
下载PDF
导出
摘要 目的 探讨阿米福汀对体外培养的中国仓鼠V79细胞和C5 7BL/ 6小鼠造血系统的放射保护作用及其在肺癌放射治疗时对肺癌组织生长的影响。方法 将体外培养的中国仓鼠V79细胞接种于培养皿后,分别给予2~10Gy的γ射线照射,用药组在照射前30min暴露于阿米福汀(1 2mmol/L) ,评价阿米福汀对照射后V79细胞存活分数的影响;给予C5 7BL/ 6无瘤小鼠腹腔注射阿米福汀(2 0 0mg/kg) 30min后进行全身照射(8Gy) ,在照射后不同时间观察外周血白细胞数量的变化;给予荷Lewis肺癌C5 7BL/ 6小鼠肿瘤局部照射10Gy ,照射前30min腹腔注射阿米福汀(2 0 0mg/kg) ,评价阿米福汀对肿瘤放疗效果的影响。结果 用药组V79细胞的集落存活分数高于单纯放射组(P <0 0 5 ) ;用药组无瘤小鼠外周血白细胞数较单纯放射组下降幅度小且恢复快(P <0 0 5 ) ;在观察的2 0d内,比较用药组和单纯放射组荷Lewis肺癌小鼠肿瘤体积,在相同时间点两组之间比较无显著性差异(P >0 0 5 )。结论 本研究从离体和在体两方面证实了阿米福汀对机体正常细胞产生放射保护的同时。 Objective To evaluate the radioprotective effects of amifostine against radiation-induced injury on cultured V79 cells in vitro and haematopoietic progenitor cells and Lewis lung cancer tissue in vivo.Methods The cultured Chinese hamster V79 cells were irradiated with 2~10 Gy of γ rays after exposure to 1.2 mmol/L of amifostine for 30 min and the survival fractions were evaluated.Amifostine (200 mg/kg) was administered intraperitoneally to C57BL/6 mice before the whole body irradiation with 8 Gy of γ rays and the white blood cell counts were measured.C57BL/6 mice bearing Lewis lung cancer cells were locally irradiated with a single dose of 10 Gy for 30 minutes after amifostine (200 mg/kg) administration intraperitonially.Results A brief exposure to amifostine protected cultured V79 cells from radiation injury.Amifostine also conducted radioprotection to haematopoietic progenitor cells of normal C57BL/6 mice.However,no reduced radiation injury effect on Lewis lung cancer tissues was observed.Conclusion Amifostine protects normal cells from radiation damage wihtout extenuation of tumoricidal potential against Lewis lung cancer.
出处 《中国呼吸与危重监护杂志》 CAS 2005年第3期181-184,共4页 Chinese Journal of Respiratory and Critical Care Medicine
关键词 阿米福汀 肿瘤 放射疗法 机体 肺癌细胞 组织损伤 Lung cancer Amifostine Radioprotection
  • 相关文献

参考文献10

  • 1Gopal R. Non-small cell lung cancer:the role of cytoprotection in treating therapy-related toxicity. J Support Oncol, 2004; 2:13~17.
  • 2Friedland J. Managing toxicities in pelvic malignancies. J Support Oncol,2004;2:19~23.
  • 3Thongprasert S, Chewaskulyong B. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer. J Med Assoc Thai, 2004; 87:1162~ 1167.
  • 4Schuchter LM, Luginbuhl WE, Meropol NJ. The current status of toxicity protectants in cancer therapy. Semin Oncol, 1992;19:742~751.
  • 5Yavuz AA, Aydin F, Yavuz MN, et al. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twiceweekly gemcitabine in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys,2001;51:974~981.
  • 6Wasserman TH, Brizel DM. The role of amifostine as a radioprotector. Oncology, 2001; 15: 1349~1354.
  • 7Phan TP, Crane CH, Janjan NA, et al. WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment. Int J Pancreatol, 2001; 29:19~23.
  • 8Spencer CM, Goa KL. Amifostine:A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs, 1995;50:1001 ~ 1031.
  • 9Koukourakis MI. Amifostine in clinical oncology:current use and future applications. Anticancer Drugs, 2002; 13: 181~209.
  • 10Small WJ. The potential role of amifostine in the treatment of carcinoma of the uterine cervix: a review. Semin Radiat Oncol,2002; 12: 68~74.

同被引文献32

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部